United States was the largest of TherapeuticsMD, Inc.’s 2 reported lines in fiscal 2025, at $1.79M — 59% of $3.02M.
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $1.00M | $1.12M | $1.79M |
| Non-U.S | $299.00K | $638.00K | $1.23M |
| Total | $1.30M | $1.76M | $3.02M |
In fiscal 2025, which ended December 31, 2025, the 2 regions TherapeuticsMD, Inc. reported in this breakdown added up to $3.02M. That was up 71.6% from $1.76M in fiscal 2024. United States was the largest region, at $1.79M or 59.3% of the total, followed by Non-U.S ($1.23M, 40.7%).
Compared with fiscal 2024, Non-U.S grew the fastest, rising 92.8% to $1.23M. Over fiscal 2023 to 2025, revenue across these regions went from $1.30M to $3.02M, a compound annual growth rate of 52.3%. United States' share of the total fell from 77.0% to 59.3% over the same years.
This breakdown covers every fiscal year from 2023 to 2025, as reported in TherapeuticsMD, Inc.'s annual filings.
TherapeuticsMD, Inc. (TXMD) breaks its revenue down by region. In fiscal 2025, its largest region was United States, with $1.79M or 59.3% of the total, followed by Non-U.S at $1.23M (40.7%).
United States was TherapeuticsMD, Inc.'s largest region in fiscal 2025, with $1.79M in revenue, 59.3% of the $3.02M reported across its 2 regions.
Of the TherapeuticsMD, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Non-U.S grew the fastest, rising 92.8% from $638.00K to $1.23M.
Every figure is taken from TherapeuticsMD, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2023 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.